Clinical Trial Update: Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CD19 and CD22 targeted CAR-T therapy for relapsed/refractory B-cell leukemia and lymphoma with safety and efficacy observations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• CD19- and CD22-targeted CAR-T therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Leukemia, B-cell, Lymphoma, B-Cell | Phase 1, Phase 2 | Status: UNKNOWN